Invention Grant
- Patent Title: Inhibiting the transient receptor potential A1 ion channel
-
Application No.: US15940253Application Date: 2018-03-29
-
Publication No.: US10428072B2Publication Date: 2019-10-01
- Inventor: Blaise S. Lippa , Xinyuan Wu , Qingyi Li , Iwona Wrona , Andrew J. Jackson , Bertrand L. Chenard , Christopher M. Liu , Guohua Liang , Matthew F. Baevsky , Richard A. Earl , Lisa Mcqueen , Jared Smit , Brett A. Cowans
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Nelsen L Lentz
- Main IPC: C07D473/08
- IPC: C07D473/08 ; A61K31/522
Abstract:
The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
Public/Granted literature
- US20180230149A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Public/Granted day:2018-08-16
Information query
